I-Synexis® LLC namuhla imemezele idatha emisha emihle evela ekuhlaziyweni okubuyela emuva okuhlaziya ukusetshenziswa kwe-DHP™ Technology esimweni somtholampilo kushicilelwe kumagazini wamanje we-American Journal of Infection Control (AJIC). Ukuhlaziya okubuyela emuva kuhlole ukusebenza kahle kwe-DHP™ Technology, ngaphezu kokuhlanza okuvamile okwenziwa ngesandla, ekwehliseni izifo ezitholwa esibhedlela (i-HAIs) egunjini labagula kakhulu (ICU) esibhedlela se-oncology yezingane. Njengobuchwepheshe obuhambisanayo bokuhlanza imvelo, i-DHP™ ibe nesandla ekwehliseni ama-HAI kulesi simo somtholampilo.
"Izinqubo ezijwayelekile zokuhlanza kanye nokubulala amagciwane zingase zinganele ezigulini ezingenaso isifo esingenwa kalula yi-HAI," kusho uDkt. Mario Melgar, uMqondisi Wezokwelapha Wokutheleleka Nokulawula.
Lolu cwaningo lwenziwe phakathi kukaJanuwari 2019 noNovemba 2020 e-ICU (PICU) yezingane e-Unidad Nacional de Oncología Pedátrica (UNOP), iNational Referral Center for Children with Cancer kanye nozakwethu womhlaba wonke wesikhungo esihola phambili somdlavuza wezingane e-US UNOP isibhedlela se-oncology sezingane esinemibhede engama-65 esiseGuatemala City, eGuatemala. Yize belandela yonke imihlahlandlela ye-CDC kanye nemithetho yokuvimbela i-HAI, i-DHP™ Technology yengezwe ekuhlanzeni okujwayelekile kwemvelo kanye nokubulala amagciwane ku-PICU ukuze kunqunywe umthelela wayo kumazinga e-HAI.
“Lolu cwaningo lukhombisa ukubaluleka kwe-DHP™ Technology. Ngijabule kakhulu ukubona ukwehla okukhulu kwezigameko ze-C. diff ku-PICU yethu,” kusho uDkt. Alicia Chang, uMnyango Wezifo Ezithathelwanayo. “Siyaqhubeka nokulandela amasu anconyiwe e-CDC okuvikela nokulawula, futhi ukungezwa kwe-DHP™ ohlelweni lwethu lokuhlanza imvelo kusisize ukuthuthukisa imiphumela yethu.”
Phakathi kuka-2019 no-2020, ukungezwa kwe-DHP™ ekuhlanzeni okujwayelekile kuphumele ekwehleni okungama-44.3% kwezehlakalo ze-HAI (umehluko wezinga lesigameko, i-IRD = -21.20, p=0.0277) ku-PICU, okuhlanganisa nokwehliswa okungama-76.4% ku-Clostridioides-associated gastroenteritis. (IRD=-8.23, p=0.0482), uma kuqhathaniswa nesikhathi sangaphambi kokufakwa kwe-DHP™. Ukwengeza, icala elilodwa kuphela lokutheleleka kwe-COVID-19 okuhlobene ne-COVID-2.52 okuhlobene nokuphefumula okungeyona inyumoniya kwenzeka e-PICU lapho i-DHP™ yafakwa khona uma kuqhathaniswa nendawo yokulawula ngaphandle kwe-DHP™ ethole ukwanda kwezifo ezitholwa esibhedlela ezingezona inyumoniya ( I-IRD=0.028; p=2). Lokhu kuhambisana nocwaningo lwakamuva olubonisa ukuthi i-DHP™ yenza i-SARS-CoV-2,3 isebenze emoyeni nasezindaweni ezingaphezulu. 61.4; p=0.386). Isigameko se-HAI asishintshanga kakhulu kwenye ingxenye yesibhedlela lapho i-DHP™ yayingafakwanga khona.
"Izifo ezitholakala esibhedlela ezifana ne-COVID-19-ezihlobene ne-pneumonia yezifo zokuphefumula ziwusongo olukhulu olungeke luqedwe ngokuphelele," kusho u-Eric Schlote, oyi-CEO ye-Synexis®. "Sijabule ngokuthi i-DHP™ Technology iyaqhubeka nokubonisa ukusebenza kahle kuzilungiselelo zomtholampilo futhi ingase inikeze esinye isendlalelo sokuvikela kuma-HAIs kanye ne-SARS-COV-2."
Iziguli ocwaningweni zazisukela eminyakeni eyi-1 kuye kwengama-22 ubudala, futhi zineminyaka yobudala eyi-7.7. Iningi (61%) kwakuyiziguli ezine-leukemia, kuyilapho insalela yatholakala inezinye izinhlobo zomdlavuza, okuhlanganisa i-sarcoma, i-blastoma ne-lymphoma. Lezi ziguli zisengcupheni enkulu yama-HAI ngenxa yesimo sazo sokuzivikela komzimba, ukuchayeka emishinini nezinqubo ezihlaselayo, kanye nezimo zezokwelapha ezikhona.4 I-DHP™ Technology yehlise amazinga e-HAI ngaphandle kokubangela noma yiziphi izehlakalo ezimbi ezihlobene nokuchayeka ku-DHP™.
Ubuchwepheshe be-Synexis® busebenzisa i-DHP™ ukuhlanza umoya nezindawo. Ama-molecule e-DHP™ ahamba endaweni evalekile ukuze ehlise amagciwane, amagciwane, isikhunta, iphunga nezinambuzane eziningi. Ikhiqizwe kusuka kumswakama we-ambient kanye ne-oksijini ekhona ngokwemvelo endaweni, i-DHP™ ingalethwa ngokuphumelelayo ezindaweni ezihlala abantu emazingeni angaphansi kwezindinganiso zokuphepha ezisebenza emoyeni ezisungulwe yi-OSHA, okuvumela ukuncishiswa kwe-microbial okuqhubekayo ngaphandle kokuphazamisa ukusebenza okuvamile nokuhamba komsebenzi.5 DHP™ is ekwazi ukuthonya ukungcola emoyeni nasezindaweni okunzima ukufinyelela kuzo.
LOKHO ONGAKUTHATHE KULESI SIHLOKO:
- The study was conducted between January 2019 and November 2020 at the pediatric ICU (PICU) at Unidad Nacional de Oncología Pediátrica (UNOP), the National Referral Center for Children with Cancer and a global partner of a leading pediatric cancer institution in the U.
- The retrospective analysis assessed the efficacy of DHP™ Technology, in addition to standard manual cleaning, in reducing hospital-acquired infections (HAIs) in the intensive care unit (ICU) of a pediatric oncology hospital.
- Additionally, only one case of hospital-acquired COVID-19-associated non-pneumonia respiratory infection occurred in the PICU where DHP™ was installed compared to a control area without DHP™ which experienced an increase in hospital-acquired non-pneumonia respiratory infections (IRD=2.
